Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ELND 005 (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use
Sponsors Elan Pharmaceuticals; OPKO Health; Transition Therapeutics

Most Recent Events

29 Nov 2011 New analyses focused on treatment effects at earlier stages of the disease using validated composite cognitive endpoints were presented at the 4th Conference Clinical Trials on Alzheimer's Disease, according to a Elan Corporation media release.
14 Sep 2011 Results published in Neurology.
20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com